The research team found the best dose to give, and WX-554 didn’t cause too many serious side effects.
The research team recruited people between 2012 and 2014. They published the results in 2016.
This trial recruited 41 people with advanced cancer. They had a number of different cancers including bowel cancer and lung cancer.
Everyone taking part took WX-554 tablets. Some people took them once a week, and some took them twice a week.
The first few people taking part in the weekly and twice weekly groups had the lowest dose of WX-554. They didn’t have any serious side effects, so the next few people had a higher dose. And so on, until they found the best dose to give. This is called a phase 1 dose escalation study
The research team looked at what happened in the body when people had WX-554. They found it reduced the amount of a certain protein in the blood. And that having WX-554 twice a week gave a more consistent result.
They also looked at how well WX-554 worked after 6 weeks of treatment, in 34 of the people who took part. It’s hard to draw any firm conclusions from a small trial. But the results showed that the cancer hadn’t grown in 20 of the 34 people (59%). And for 2 of these people, the cancer stayed the same size for many months.
WX-554 did cause some side effects, but many of them were mild or short lived. About 8 out of 10 people (81%) had at least one side effect.
The most common side effects were:
- extreme tiredness (fatigue)
- skin reactions
- a drop in appetite
- feeling sick
Four people taking part had more serious side effects, including a change in heart rhythm and a change in levels of liver enzymes. Two people were able to re-start treatment a lower dose once the side effect had gone. And two people stopped treatment because of the side effects they were having.
The research team concluded that they had found the best dose of WX-554 to use. And that it didn’t cause too many serious side effects.
They suggest that it is looked at in other trials, either on its own or in combination with another treatment.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.